BALDERTON-CAPITAL
7.2.2020 13:03:07 CET | Business Wire | Press release
Balderton Capital announces today that it has hired two new General Partners. Rana Yared joins from Goldman Sachs, where she was Partner in the Principal Strategic Investments team. David Thévenon joins from SoftBank’s Vision Fund, where he was one of the initial Partners.
Bernard Liautaud, Managing Partner of Balderton Capital, said: "I am delighted to welcome Rana and David to the partnership. They both bring outstanding experience in investing globally in the technology ecosystem. With her team at Goldman Sachs, Rana has built one of the best fintech and AI portfolios across the US and Europe. And within Softbank, David has participated in the growth journeys of companies as diverse as Didi in China, Grab in Singapore, Lemonade and SoFi in the US. The opportunity in the European tech ecosystem continues to expand at a rapid pace, and Rana and David will play a key role in our investment strategy in the European venture space."
During her time at Goldman Sachs, Rana’s team invested $2bn in 80 companies, with a strong focus on fintech. As one of Goldman’s best-known tech investors, Rana led the US and European Principal Strategic Investment (PSI) teams and served on Goldman’s Growth Equity Investment committee. She spent five years on the board of the fixed income trading platform Tradeweb, until it went public in April 2019 with a market capitalisation of $6bn. Rana also brought the artificial intelligence platform Kensho to Goldman Sachs. Kensho was ultimately sold to S&P Global for $550m in March 2018.
Rana currently sits on the boards of Nutmeg, Vestwell, NAV, Pensando, Digital Reasoning, Veem, and NYSHEX. She joined Goldman Sachs as an analyst in 2006 and was named Managing Director in 2013 and Partner in 2018.
Rana Yared said: “My greatest passion is working closely with founders and their teams to build new companies, and I am delighted to be able to devote myself to this when I join Balderton. In recent years, Europe has established itself as a tech leader and is brimming with potential and opportunity. I am excited to move back to the European side of the Atlantic and to begin seeking out and working with the next generation of exciting tech companies.”
During his five-year tenure at SoftBank, David led investments in Didi Chuxing, the world's leading mobile transportation platform; Grab, Southeast Asia's leading superapp; Ola, India's leading ride-sharing platform; Lemonade, the digital insurance company powered by AI and driven by social good; SoFi, the American online personal finance platform; and Kabbage, one of the leading US SMB lending platforms. David was also involved in SoftBank's investments in 99 in Brazil (bought by Didi) and Legendary Pictures in the US (sold to Wanda Group).
Before joining SoftBank, David had a 10-year career at Google, where he worked on partnerships for products that touched billions of users, including leading global product and business partnerships for Google's Android platform.
David Thévenon said: “Five years ago I left Google to focus on venture investing at SoftBank and I felt privileged to meet, invest and work with some of the most innovative and visionary founders, supporting them as they grew into market-leading companies. Joining Balderton will allow me to continue this for European-founded companies, and I am truly excited about the opportunity ahead.”
[ENDS]
About Balderton:
Balderton Capital is a London-based venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn. Balderton’s most recent funds were the early-stage Balderton VII, raised in November 2019, and Liquidity I, Europe’s first venture fund dedicated to secondary investments in European-founded, growth-stage technology startups, raised in October 2018. Previous exited investments include Betfair (FTSE: BET), Magic Pony (Twitter), NaturalMotion (Zynga), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Among Balderton’s current portfolio of over 90 companies are Aircall, Carwow, Citymapper, Contentful, Darktrace, Depop, GoCardless, The Hut Group, Kobalt Music, Nutmeg, Peakon, Prodigy Finance, Revolut, SOPHiA Genetics, Tessian, Vestiaire Collective, Vivino, Voi Technology, and Zego.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom